MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of ...

New research shows GLP-1 drugs may be linked to a twofold increase in the risk of wet AMD among people with diabetes.

GLP-1 RAs may significantly increase the risk of neovascular age-related macular degeneration in older adults with diabetes.

Semaglutide, a synthetic analog of glucagon-like peptide-1 (GLP-1), has garnered attention for its intriguing properties and potential implications in various r ...

The added layers of meaning we’ve piled onto food often lead to overeating, energy overload, and metabolic-associated ...

T1D Exchange, a nonprofit organization that drives meaningful research and improvement in care and outcomes in type 1 ...

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...

Vertex is trimming its Rhode Island footprint on the back of a scrapped “cells plus device” program in diabetes, leaving 125 staffers out of a job. | The company is merging its three buildings at its ...

The layoffs will heavily affect Vertex’s operations in Rhode Island, where the biotech will consolidate three facilities into ...

Canada: A recent observational cohort study from Canada revealed that older diabetic patients taking GLP-1 receptor ...

Among older patients with diabetes, glucagon-like peptide 1 receptor agonists were associated with an increased risk for ...

Canadian researchers find that taking semaglutide increases the chances of developing neovascular age-related macular ...